CN102429929B - Compound fermented cordyceps fungus powder and taurine combined drug - Google Patents
Compound fermented cordyceps fungus powder and taurine combined drug Download PDFInfo
- Publication number
- CN102429929B CN102429929B CN 201110177618 CN201110177618A CN102429929B CN 102429929 B CN102429929 B CN 102429929B CN 201110177618 CN201110177618 CN 201110177618 CN 201110177618 A CN201110177618 A CN 201110177618A CN 102429929 B CN102429929 B CN 102429929B
- Authority
- CN
- China
- Prior art keywords
- mycopowder
- medicine
- fermented cordyceps
- fermented
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a compound fermented cordyceps fungus powder and taurine combined drug, discloses the weight ratios of various raw material compositions of the compound fermented cordyceps fungus powder and taurine combined drug, and provides preparation steps and the method of the compound fermented cordyceps fungus powder and taurine combined drug. Capsules, particles and tablets of compound fermented cordyceps fungus powder and taurine combined drug can be prepared according to the pharmaceutically accepted dosage; and the compound fermented cordyceps fungus powder and taurine combined drug can be used for resisting aging, resisting fatigue, resisting shock, resisting ray radiation, calming, hypoxia tolerance and improving immunity.
Description
The application is dividing an application of domestic formerly patent of invention.And enjoyment domestic priority.Formerly patent application state is China, and the application number of formerly patent application is 201010278624.1, and the applying date is on 09 13rd, 2010, and patent name is " compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) composition of medicine ".
Technical field
Technical characterictic of the present invention is compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) composition of medicine formula, preparation method, purposes.
Background technology
Current war in the world, natural disaster, survival and development pressure make people's physical and mental health enjoy challenge.This challenge to the harm of human body psychosoma, must be opened up this emerging medical treatment field not second to traditional disease.China is a country that natural disaster takes place frequently, and earthquake, great drought, flood, freezing, typhoon, mud-rock flow belong in the world that the condition of a disaster takes place frequently and one of serious country; In the national economic development process, international financial crisis, trade dispute are frequent, even the prestige of war association; Peaceful development also has major disease not radical cure and disease transmission, the aging of population challenge period, especially will improve veteran revolutionaries, veteran cadre, old expert, all old man's life cycle, quality of life.In order to tackle the challenge of all these natural and man-made calamities, if invention has the medicine that improves China the army and the people body immunity, enhancing resisting fatigue energy, excites defying age vitality, the calm psychology of adjusting, make China the army and the people more effectively tackle above-mentioned human survival and development significant challenge, improve national power, have strategic economic benefit and social benefit.
Cordyceps is called for short Cordyceps, is the famous and precious natural drug that is handed down of the mankind over the past thousands of years, and ill curing the disease without treating diseases and making health-care, and is fit to all people and takes, and there is no insulting side effect and untoward reaction.But its resource-constrained, Jiangxi Traditional Chinese Medicine Factory utilizes a large amount of suitability for industrialized production of natural living Chinese caterpillar bacterium artificial fermentation, for production famous medicine fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) is supplied raw materials, this product content is peacilomyce hepiahi Cs-4 mycopowder, perhaps be called again fermented Cordyceps powder, be commonly called as the Cordyceps powder, Cordyceps powder, Cordyceps extract, ferment cordyceps sinensis powder etc.The peacilomyce hepiahi bacterium powder is separating obtained Cordyceps from fresh Cordyceps fungus (cordyceps sinensis (Berk) sacc)---peacilomyce hepiahi (Paecilomyces hepiali Chen ﹠amp; Dai) product of making through liquid submerged fermentation cultivation, filtration, drying, pulverizing, the present invention is defined as fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) to this fermenting and producing Cordyceps powder out, has another name called Cordyceps powder.Cordyceps is the traditional famous and precious medicated nourishing product of China, and the flat sweet in the mouth of its property has the function that tonifying the lung kidney, cough-relieving are coughed, benefit is deficient, support vital essence.According to clinical research, Cordyceps has ten large functions: 1. antibiotic, and 2. immunomodulating, 3. anticancer, 4. antiinflammatory, 6. 5. nourishing kidney improves adrenal cortex alcohol content, 7. arrhythmia, 8. resisting fatigue, 9. eliminating phlegm and relieving asthma, 10. tranquilizing soporific.Utilizing the large industrial fermentation of modern biological project to produce fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) is that historical contribution and the historical productivity are progressive, but the reach a small amount of heavy metal ion and high price iron ion and miscellaneous bacteria that are mingled with in production process just make good medicine also have blemish in an otherwise perfect thing, and slight stomach upset sense is arranged after minute quantity people takes.Remove above-mentioned slight side effect and the slight untoward reaction of the fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) of artificial fermentation production, adding increases its physiological function, can produce new compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) preparation.
Alprostadil, the former name prostaglandin E
1, become drug use less than 30 years research histories, separate from the human seminal fluid the earliest, so be called prostaglandin E
1, in fact it is present in human body and all histiocytes of mammal and body fluid, for fear of with correct to misread, country changes its Alprostadil by name, it is also the material of the natural extensive physiological function character of tool.Its discovery has caused a sensation the world, and nineteen eighty-two has three scientists to obtain simultaneously Nobel Prize.Its physiological function has almost contained all great physiological functions of the mankind.The application of prostaglandin has been deep into the every field (Li En, prostaglandin and modern medicine, the 1st edition, Beijing: People's Health Publisher, 1985, synopsis) of medical science, that is to say that it relates to each sick treatment and prevention of planting.Its ultimate principle is: the edible oil that we eat every day, under the serial enzymes effect, first generate gamma-Linolenic acid in vivo, and then generate dihomo-gamma-linolenic acid, generate at last Alprostadil.When human body physiological function needed, it produced in the various histiocytes of human body and body fluid immediately, the various physiological functions of balance the body, and circulate in the organ major parts such as lung, liver, kidney through blood and be inactivated and excrete.the inventor passes through nearly 30 years research theories and facts have proved, especially modern medical theory and facts have proved: lack edible oil at human body, or worn with age, the endocrine disturbance, chemical contamination, rule of life is upset, tired anxiety etc. lose in body must enzymatic activity or body in must enzyme quantity not all have influence on Alprostadil and secrete in vivo and make all diseases of human body generation, if replenish a certain amount of Alprostadil in body, ill people can reach a cure, do not have the people of disease can anti-disease, defying age, resisting fatigue, anxiety, anti-insomnia, keep lasting strong, full of vitality, thinking is clear, improve quality of life, be called again life source material.Alprostadil preparation becomes sales volume the first medicine in cardiovascular medicament at home.But by separate the Alprostadil resource-constrained with histiocyte from the mammal seminal fluid, so USA and Europe, Japanese chemosynthesis prepare Alprostadil, China Norman Bethune Medical University, Jilin Province Medicine Research Institute have been opened up one and have been utilized the specialties of the Northeast Radix Oenotherae erythrosepalae oil to make raw material, extract compound enzyme catalysis from sheep spermary, the semi-synthetic route of synthetic Alprostadil prepares Alprostadil, has solved raw material sources restriction bottleneck.The inventor improves again white medical university and the Jilin medicine grinds semi-synthetic route, and invention gas, liquid, solid three's co-absorbed and compound enzyme immobilization carrier and suitability for industrialized production Alprostadil biochemical reactor (China such as inventor is patent of invention formerly, patent name: Alprostadil production of raw medicine technique, the patent No.: 961211350).Realize the suitability for industrialized production Alprostadil, realize that process cycle is external 1/7th, cost is external 1/10th, and quality is the standard substance that are better than external famous expert.The alternative foreign standard product (380000 yuans/gram of valency) of front profit your standard substance (7000 yuans/gram of valency) of ground that Jilin medicine inspecting institute and national drug biological products assay institute provide with the inventor.The Alprostadil crude drug of inventor preparation and preparation have overcome injection pain, refrigerator accumulating, the content three big world difficult problems that fall progressively.Serial China of the present invention formerly patent of invention solved that the large suitability for industrialized production of alprostadil liposome preparation is energy-conservation, de-carbon, zero emission technique, equipment, solved fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) fermentation tail gas dedusting, degerming, except phage, eliminate the unusual smell, the increment of de-carbon oxygen enrichment and recycled Processes and apparatus.Make Alprostadil even former the and material preparation large suitability for industrialized production of fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) enter international most advanced level and have the protection of independent IP at technique, equipment, quality, scale, cost, consumption, energy-conservation, reduction of discharging, de-carbon.Substantially having possessed exploitation improves national power, improves army's fighting capacity, improves medicine comprehensive Intellectual Property Right Protection System of people's life quality.
Summary of the invention
One. compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) composition of medicine and preparation thereof:
(1). compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine and preparation process and method:
1, each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine is:
Illustrate: here taurine or or baicalin, its molecular formula is C
21H
18O
11, molecular weight is 446.35, its weight fraction in formula is 0.0500-0.1000.
2. compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine preparation process and method are:
2.1 the fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) of drying is pulverized, is made 120-150 order fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder);
2.2 taurine or baicalin, vitamin C are dissolved in water for injection, and making proportion is the 1.0-1.1 aqueous solution, is that 8% analytical pure hydrochloric acid solution adjust pH is 4.0-6.0 with mass percent, then solution is crossed degerming through 0.22 μ m membrane filtration;
2.3 under 100 grades of sterile purification environment, the 120-150 order fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) of 2.1 steps preparation is put into boiling coating-boiling drier, press the well-established law operation, controlling introducing filtrated air negative pressure makes fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) boiling highly be 400mm-500mm, at 40-50 ℃ of temperature, the proportion that 2.2 steps were made is that the 1.0-1.1 aqueous solution is by the vaporific intensive place of fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) particle that is sprayed on boiling in nozzle, to fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) coating, be controlled in 30-60 minute coating complete, this temperature range airpillow-dry 20-30 minute, make dry solids moisture less than 1% again,
2.4 press the dosage that pharmaceutics allows, under 100 grades of sterile purification environment, well-established law is made capsule, granule, the tablet of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine.
(2). compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine and preparation process and method:
1. each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine is:
Here taurine or ginsenoside Rg
1, it is that Araliaceae Radix Ginseng or Radix Notoginseng extraction separation obtain monomer, molecular formula is C
42H
72O
14, molecular weight is 830.03, weight ratio is 0.0500-0.1000 in formula.
2. preparation process and the method for compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine are:
2.1 with anhydrous alcohol solution Alprostadil or ginsenoside Rg
1Extremely just dissolve complete, make Alprostadil or ginsenoside Rg
1Nearly saturated ethanol solution;
2.2 beta-schardinger dextrin-is dissolved in part water for injection, to dissolve complete just, make near saturated solution, be that 8% analytical pure hydrochloric acid solution adjust pH is 5.0-5.5 with mass percent;
2.3 Alprostadil or ginsenoside Rg with the preparation of 2.1 steps
1Ethanol solution under 60-100 rev/min of stirring, room temperature drops in the beta-schardinger dextrin-near saturated solution of 2.2 step preparations, to Alprostadil dissolving or ginsenoside Rg
1Fully, make Alprostadil or ginsenoside beta-schardinger dextrin-comprise solution;
2.4 the fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) of drying is pulverized, is made 120-150 order fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder);
2.5 taurine, reduced glutathion under 60-80 rev/min of stirring, are dissolved in remaining water for injection, and making proportion is the 1.0-1.2 aqueous solution, then goes on foot with 2.3 Alprostadil or the ginsenoside Rg who prepares
1The solution that comprises of beta-schardinger dextrin-add, stir, be then that 8% analytical pure hydrochloric acid solution adjust pH is 5.0-5.5 with mass percent, at last solution is crossed degerming through 0.22 μ m membrane filtration;
2.6 under 100 grades of sterile purification environment, the 120-150 order fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) of 2.4 steps preparation is put into boiling coating-boiling drier, press the well-established law operation, controlling introducing filtrated air negative pressure makes fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) boiling highly be 400mm-500mm, at 40-50 ℃ of temperature, 2.5 sterile liquid medicines made of step by the vaporific intensive place of fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) particle that is sprayed on boiling in nozzle, to fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) coating, be controlled in 30-60 minute coating complete, this temperature range airpillow-dry 20-30 minute, make dry solids moisture less than 1% again,
2.7 press the dosage that pharmaceutics allows, under 100 grades of sterile purification environment, well-established law is made capsule, granule, the tablet of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) group B composition of medicine.
(3). compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine and preparation process method thereof:
1. each component raw material weight ratio of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine is:
Illustrate: danshensu or curcumin here, the curcumin molecular formula is C
21H
20O
6,, molecular weight is 368.37, its weight ratio is 0.1000-0.3000 in formula.
Danshensu is that danshensu is the water solubility extract of Salvia miltiorrhiza Bge, is the main component of FUFANG DANSHEN DIWAN, chemistry β by name-(3,4-dihydroxy phenyl) lactic acid.
Gamma-Linolenic acid claims again vitaminF, and the initiation material of its preparation is Radix Oenotherae erythrosepalae oil.
2. compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine preparation process and method are:
2.1 with the anhydrous alcohol solution gamma-Linolenic acid, make the gamma-Linolenic acid ethanol solution, or gamma-Linolenic acid and curcumin be dissolved in dehydrated alcohol jointly, even make the solution that gamma-Linolenic acid and curcumin are dissolved in dehydrated alcohol jointly;
2.2 beta-schardinger dextrin-is dissolved in part water for injection, to dissolve complete just, make near saturated solution, be that 8% analytical pure hydrochloric acid solution adjust pH is 5.0-5.5 with mass percent;
2.3 under 60-100 rev/min of stirring, room temperature drops in the beta-schardinger dextrin-near saturated solution of 2.2 steps preparation with the ethanol solutions of 2.1 step preparations, till the gamma-Linolenic acid dissolve complete, or gamma-Linolenic acid and curcumin be all till dissolve complete,
Make the beta-cyclodextrin inclusion compound solution of gamma-Linolenic acid, or the solution that jointly comprised by beta-schardinger dextrin-of gamma-Linolenic acid and curcumin;
2.4 the fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) of drying is pulverized, is made 120-150 order fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder);
2.5 with danshensu under 60-80 rev/min of stirring, be dissolved in the comprising in solution of beta-schardinger dextrin-of the gamma-Linolenic acid of 2.3 step preparations, and with remaining water for injection under the prerequisite that stirs, adjusting solution proportion is 1.0-1,1, be that 8% analytical pure hydrochloric acid solution adjust pH is 5.0-5.5 with mass percent again, at last solution crossed degerming through 0.22 μ m membrane filtration; Or curcumin is when substituting danshensu, it is 1.0-1.1 with remaining water for injection adjustment solution proportion that the gamma-Linolenic acid of 2.3 step preparations and curcumin are comprised solution by beta-schardinger dextrin-jointly, be that 8% analytical pure hydrochloric acid solution adjust pH is 5.0-5.5 with mass percent again, at last solution crossed degerming through 0.22 μ m membrane filtration;
2.6 under 100 grades of sterile purification environment, the 120-150 order fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) of 2.4 steps preparation is put into boiling coating-boiling drier, press the well-established law operation, controlling introducing filtrated air negative pressure makes fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) boiling highly be 400mm-500mm, at 40-50 ℃ of temperature, the 2.5 danshensu sterile liquid medicines made of step or curcumin sterile liquid medicine (when replacing danshensu by curcumin) by the vaporific intensive place of fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) particle that is sprayed on boiling in nozzle, to fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) coating, be controlled in 30-60 minute coating complete, this temperature range airpillow-dry 20-30 minute, make dry solids moisture less than 1% again,
2.7 press the dosage that pharmaceutics allows, under 100 grades of sterile purification environment, well-established law is made capsule, granule, the tablet of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine.
Two. the advantage of medicine of the present invention:
(1). compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine advantage:
1. compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A has increased taurine on fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) basis; main disease curing range is controlled the kidney effect except keeping fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) to control lung; expand to and control hypertension, hyperglycemia, cardiovascular and cerebrovascular disease, resisting fatigue, defying age, shock, radioprotective.
2. taurine is also intrinsic biological active substances in animal body, and its function has:
2.1 antiinflammatory, antiallergic;
2.2 immunologic enhancement;
2.3 ischemic cardiac myocyte, hypoxic pulmonary arterial endothelial cell, Hypoxic cerebral arteries endotheliocyte are had protective effect;
2.4 the increase myocardial contraction, arrhythmia, shock, defying age, resisting fatigue, radioprotective;
2.5 blood pressure lowering, blood sugar lowering;
2.6 arteriosclerosis;
2.7; Improve one's memory, the treatment dysthymia;
2.8 anti-intestinal endotoxin shifts, treatment viral myocarditis, treatment upper respiratory tract infection.
Baicalin is that the plant scutellariae,radix extracts monomer, above-mentioned functions is also arranged, the ginsenoside Rg
1The taurine above-mentioned functions is also arranged.
3. compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A has also increased the antioxidant vitamin C, the present invention also uses taurine and vitamin C to carry out coating to fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder), avoid fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) in manufacturing, accumulating, use procedure in vitro and in vivo oxidation, peroxidating and the side effect that produces and bad should; It also is used for: vitamin C deficiency prevention and treatment, the acute and chronic infectious disease or after being ill convalescent period, During Wound Healing replenish, the cardiogenic shock treatment, hepatic injury and the treatment of chronic poisoning hepatic injury, be used for anemia, anaphylaxis dermatosis treatment, promote wound healing, to flu, cancer, hyperlipidemia treatment.
4. the present invention produces compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A under 100 grades of sterile purification environment, than injection production rank also high (injection is the local laminar flow environment purification under ten thousand grades), also have the medicinal liquid Entkeimung to reach except high price precipitation of iron ions thing, except insoluble particle, favourable raising product quality avoids miscellaneous bacteria and oxidant to make product rotten.This is the production technology of uniqueness of the present invention;
(2). compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine advantage:
1. compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) B is at the upper Alprostadil that increases in compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A formula basis, except keeping compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A treatment and pre-diseases prevention kind, because Alprostadil has antibody mediated immunity complex exceptional function in the human body of removing, make antigen not reach in vivo morbidity concentration, antigen is entered in body in time please be removed, both made morbidity, disease is very light.Also have inhibition tumor cell, the differentiation tumor cell develops to normal cell.Emphasis increases antitypy unknown virus infectious disease, biochemical reagents viral disease and the infectious disease known, unknown retrovirus of preventing and treating hostile nations.Also emphasis increases prevention and treats the sick kind such as tumor, acquired immune deficiency syndrome (AIDS), serious symptom hepatitis, viral hepatitis.Therefore compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) B basically can reach wartime, extraordinary serious natural calamities period, peaceful development and improves the needs that the army and the people's muscle power, psychology are deposited stressed, vitality, national power and answering pressure period.
2. the present invention replaces vitamin C in compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A with the antioxidant reduced glutathion, and reduced glutathion is also the important physiologically substance that exists in human body.Participate in the interior tricarboxylic acid cycle of body and carbohydrate metabolism, promotion fat, protein metabolism, make human body obtain high-energy; Detoxifcation; Lonizing radiation, chemical substance, damage there is protective effect; Antiallergic; Protect the liver eye protection; Symptom palliates a disease.
3. medicine of the present invention is all intrinsic with human body or natural drug is made raw material, finds a swollen seat of local government ill medicine in quality, curative effect, safety three aspects: quality higher but deliver at newspaper than nearest U.S. a company on the net.A kind of medical treatment Various Diseases developing direction of exploitation is arranged in the world, and with saving resource, energy-saving and emission-reduction facilitate medication.Medicine of the present invention is more advanced than them, and unique distinction is more arranged.
4. compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B carries out coating with taurine and reduced glutathion to fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder), and coating effect in compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A is also arranged.
5. preparation compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B method also has the advantage of preparation compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A.
(3). compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine advantage:
1. medicine of the present invention is fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) and the combination of natural product danshensu.Radix Salviae Miltiorrhizae have defying age, coronary artery dilator, inhibition platelet T XA
2Synthetic, anticoagulation, improve microcirculation, arteriosclerosis, anti-oxidative damage, blood fat reducing, inhibition endogenous cholesterol synthetic, to liver protection and anti-fibrosis effect, sedation, antitumor action.Curcumin is that zingiberaceous plant Dioscorea zingiberensis rhizome extracts monomer, and the above-mentioned effect of danshensu is also arranged.
2. medicine of the present invention is with gamma-Linolenic acid, and namely vitaminF is antioxidant, and strong reducing property is arranged, and it derives from Radix Oenotherae erythrosepalae oil.VitaminF is intrinsic material in human body.The physiological function of vitaminF has: defying age, arteriosclerosis, guarantor's kidney and control renal insufficiency, blood pressure lowering, blood sugar lowering, blood fat reducing, fat-reducing, skin whitening, anti-gastric-ulcer, antiinflammatory, control women's premenstrual syndrome, control carbuncle of breast.
3. medicine of the present invention comprises vitaminF with cyclodextrin, and the vitaminF that comprises with cyclodextrin again and curcumin are to fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) coating.Prevent fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) oxidation in vivo and in vitro and peroxidating.
4. compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine is also to prepare under strict sterile purification condition, preparation compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine is also arranged and prepare attached side's fermented Cordyceps powder (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine advantage.
The specific embodiment:
Embodiment 1:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine is:
Here taurine or baicalin, the baicalin components by weight is 0.05.
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine are described with the front.
Embodiment 2:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine is:
Here baicalin or taurine.The taurine components by weight is 0.10.
Preparation method and the step of multiple compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine of the present invention are described with the front.
Embodiment 3:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine is:
Here taurine or baicalin, the baicalin components by weight is 0.10.
The preparation of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine
Method and step are described with the front.
Embodiment 4:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine is:
Here taurine or baicalin, the baicalin components by weight is 0.05
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine are described with the front.
Embodiment 5:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine is:
Here taurine or baicalin, the baicalin components by weight is 0.08.
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) A composition of medicine are described with the front.
Embodiment 6:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine is:
Here ginsenoside Rg
1Or taurine, the taurine components by weight is 0.4500.
Preparation process and the method for compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine are described with the front.
Embodiment 7:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine is:
Here taurine or ginsenoside Rg
1, ginsenoside's components by weight is 0.1000.
Preparation process and the method for compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine are described with the front.
Embodiment 8:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine is:
Here taurine or ginsenoside Rg
1, ginsenoside's components by weight is 0.1000.
Preparation process and the method for compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine are described with the front.
Embodiment 9:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine is:
Here taurine or ginsenoside Rg
1, ginsenoside's components by weight is 0.0500.
Preparation process and the method for compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine are described with the front.
Embodiment 10:
Each raw material components weight ratio of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine is:
Here taurine or ginsenoside Rg
1, ginsenoside's components by weight is 0.0760.
Preparation process and the method for compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) B composition of medicine are described with the front.
Embodiment 11:
Each component raw material weight ratio of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine is:
Here danshensu or curcumin, the curcumin components by weight is 0.1000.
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine are described with the front.
Embodiment 12:
Each component raw material weight ratio of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine is:
Here danshensu or be curcumin, the curcumin components by weight is 0.3000.
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine are described with the front.
Embodiment 13:
Each component raw material weight ratio of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine is:
Here danshensu or be curcumin, the curcumin components by weight is 0.3000.
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine are described with the front.
Embodiment 14:
Each component raw material weight ratio of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine is:
Here danshensu or be curcumin, the curcumin components by weight is 0.1000.
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine are described with the front.
Embodiment 15:
Each component raw material weight ratio of compound fermented aweto mycopowder (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine is:
Here curcumin or be danshensu, the danshensu components by weight is 0.37.
Preparation method and the step of compound fermented aweto mycopowder of the present invention (peacilomyce hepiahi Cs-4 mycopowder) C composition of medicine are described with the front.
The pharmacodynamics demonstration test: following test is all to entrust the test of the Experimental Animal Center well-established law of specialty.
1. defying age test:
1.1 the spontaneously hypertensive rat model with 4 monthly ages.Be divided into food and contain Oleum Helianthi 2.4%, contain the treatment group that oleum lini core oil 7.9% matched group and food contain the feedstuff of medicine 3% of the present invention, its crapulous syncope contains 15 groups of the medicines that medication therapy groups of the present invention is divided again the preparation of embodiment 1-15 example, totally 17 groups.Every group 12, experiment is to getting hematometry triglyceride meansigma methods and highdensity lipoprotein-cholesterol meansigma methods 16 weeks.Result of the test sees Table:
1.2 get the healthy mice model, every 18-20g, 10 every group.Matched group was with oleum lini 4ml/kg gavage 10 days, and 15 groups for the treatment of groups are respectively with the each 200mg/kg gavage of the medicine of the present invention of embodiment 1-15, every day twice, gavage 10 days.Blood sampling in 1 hour after the last administration is with H
2O
2Be substrate, in ultraviolet spectrophotometer 230nm place's survey trap value, to fill with H in the oleum lini Mouse Blood
2O
2It is 100% that meansigma methods is made as the resistive to hydrogen peroxide enzyme activity.With H in medicine group Mouse Blood of the present invention
2O
2Reduce meansigma methods divided by filling with H in Caulis et Folium Lini line of oils Mouse Blood
2O
2Meansigma methods is resistive to hydrogen peroxide enzyme activity improvement value.Result of the test is as follows:
2. resisting fatigue, hypoxia endurance test:
Healthy mice, body weight 18-22g, random packet.Two groups of matched groups, 10 every group, every caudal vein injecting normal saline 0.3ml organizes and tail vein injection protocatechualdehyde 300mg/kg (being dissolved in the 0.5ml normal saline) group; Treatment group tail vein injection medicine 300mg/kg of the present invention water extract concentrates in the water for injection of 0.5ml volume, every group of 10 mices.After medication 5 minutes, place in the wide mouthed bottle of airtight normal pressure 1000ml.Calculate and respectively to organize mouse survival average time.Result of the test is as follows:
3. raising immunity:
3.1 nonspecific immunity: healthy mice, body weight 18-20g.15 of matched groups, every day, normal saline 0.5ml gavage was 2 times.15 groups of medicine gavage groups of the present invention, are used 500mg/kg medicine gavage of the present invention, every day 2 times at every turn by 15 every group.Put to death afterwards in 10 days, and measured blood rosettes vigor by measuring thymosin rosettes vigor method (national drug standards have been stipulated algoscopy).Take normal saline matched group blood piece rare colored vigor as 100%.Calculate relative activity, relative activity is higher, and immunity is stronger.Result of the test is as follows:
3.2 specific immunity: healthy mice, body weight 18-20g.15 of matched groups, every day, normal saline 0.5ml gavage was 2 times.15 groups of medicine gavage groups of the present invention, are used 500mg/kg medicine gavage of the present invention, every day 2 times at every turn by 15 every group.Put to death afterwards in 15 days, and measured the anti-sheep red blood cell (SRBC) antibody titer meansigma methods that anti-sheep red blood cell (SRBC) antibody test in blood serum (entrusting the Experimental Animal Center test) obtains.And tire as 100% take normal saline gavage group, it is higher that each group of calculating is resisted sheep red blood cell (SRBC) antibody relative potency mutually, and immunity is stronger.Result of the test is as follows:
4. sedation: matched group: injection 0.1ml water for injection in 1 tricorn of conscious dogs, test group: at matched group conscious dogs side injection of brain water for injection after 48 hours, contain again the aqueous extract 0.2ml of medicine 2mg of the present invention at the side injection of brain, from injection embodiment 1 medicine, injected next embodiment medicine aqueous extract every 48 hours.Inject and began to measure the brain wave slow wave in rear 10 minutes and occur and observe dog to have or not sedation.Result of the test is as follows:
5. shock: healthy mice, body weight 18-20g.20 of endotoxin groups, lumbar injection endotoxin 300mg/kg (being dissolved in the 0.5ml normal saline); Test group: get at random 10 of endotoxin injection mices, lumbar injection medicine 300mg/kg of the present invention aqueous extract (being dissolved in 0.5ml water for injection) is immediately observed to mice existence digit rate in medicine of the present invention 6 hours.Put to death mice after 6 hours, core, liver, kidney, brain, measure respectively malonaldehyde in these tissues (MDA) amount and endotoxin.Take endotoxin group MDA content as 100%, calculate the relative MDA% of test group.Result of the test is as follows:
6. anti-light radiation: healthy mice, body weight 18-20g.10 of matched groups are fed water for injection 1.0ml, every day 2 times at every turn; Test group is fed medicine 300mg/kg of the present invention, every day 2 times at every turn.Shine after 30 minutes at medicine feed after 5 days
60C
o9.0GY1 inferior.Medicine feed is 7 days again, and the existence mice is put to death end product malonaldehyde (MDA) amount of surveying lipid peroxidation in blood, the heart, liver, kidney, brain and feeds the contrast of water for injection group.Take matched group MDA content as 100%, the relative MDA% of experiment with computing group.Result of the test is as follows:
Above pharmacodynamics demonstration test as seen, medicine of the present invention, improve the army and the people's fighting capacity, viability needs in the time of can satisfying war, burst natural disaster fully, in peacetime, can satisfy the army and the people fully improves work energy, prolongation work group age, height old people's life-span, improves old people's self-care ability and vitality needs, in a word, medicine tool of the present invention improves national power substantial economics and great social benefit.
Claims (2)
1. compound fermented aweto mycopowder composition of medicine, is characterized in that, each raw material components weight ratio is:
Fermented Cordyceps powder 0.30-0.70
Taurine 0.45-0.90
Vitamin C 0.10-0.20
Water for injection evaporates into when dry only, is fermented Cordyceps powder weight 15-20 times;
Preparation process and the method for compound fermented aweto mycopowder composition of medicine are:
1.1 the fermented Cordyceps powder of drying is pulverized, is made 120-150 order fermented Cordyceps powder;
1.2 taurine, vitamin C are dissolved in water for injection, and making proportion is the 1.0-1.1 aqueous solution, is that 8% analytical pure hydrochloric acid solution adjust pH is 4.0-6.0 with mass percent, then solution is crossed degerming through 0.22 μ m membrane filtration;
1.3 under 100 grades of sterile purification environment, the 120-150 order fermented Cordyceps powder of 1.1 steps preparation is put into boiling coating-boiling drier, press the well-established law operation, controlling introducing filtrated air negative pressure makes the fermented Cordyceps powder boiling highly be 400mm-500mm, at 40-50 ℃ of temperature, 1.2 proportions made of step be the 1.0-1.1 aqueous solution by the vaporific intensive place of fermented Cordyceps powder particle that is sprayed on boiling in nozzle, to the fermented Cordyceps powder coating, be controlled in 30-60 minute coating complete; This temperature range airpillow-dry 20-30 minute, make dry solids moisture less than 1% again;
1.4 press the dosage that pharmaceutics allows, under 100 grades of sterile purification environment, well-established law is made capsule, granule, the tablet of compound fermented aweto mycopowder taurine composition of medicine.
2. according to the described compound fermented aweto mycopowder of claim 1 composition of medicine, it is characterized in that, be used for defying age, resisting fatigue, shock, anti-light radiation, calmness, anoxia enduring, raising immunity purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110177618 CN102429929B (en) | 2010-09-13 | 2010-09-13 | Compound fermented cordyceps fungus powder and taurine combined drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110177618 CN102429929B (en) | 2010-09-13 | 2010-09-13 | Compound fermented cordyceps fungus powder and taurine combined drug |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010278624 Division CN101953857A (en) | 2010-09-13 | 2010-09-13 | Compound fermented cordyceps sinensis bacterium powder (paecilomyces hepiali Cs-4 bacterium powder) composite medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102429929A CN102429929A (en) | 2012-05-02 |
| CN102429929B true CN102429929B (en) | 2013-11-06 |
Family
ID=45978515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110177618 Active CN102429929B (en) | 2010-09-13 | 2010-09-13 | Compound fermented cordyceps fungus powder and taurine combined drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102429929B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1507796A (en) * | 2002-12-15 | 2004-06-30 | 钱泽乐 | Multifunctional full-nutrient powder |
| CN1895340A (en) * | 2006-06-23 | 2007-01-17 | 易青 | Sobering-up composition |
| CN101716256A (en) * | 2009-12-18 | 2010-06-02 | 威海康博尔生物药业有限公司 | Preparation used for strengthening immunity and inhibiting tumor |
-
2010
- 2010-09-13 CN CN 201110177618 patent/CN102429929B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1507796A (en) * | 2002-12-15 | 2004-06-30 | 钱泽乐 | Multifunctional full-nutrient powder |
| CN1895340A (en) * | 2006-06-23 | 2007-01-17 | 易青 | Sobering-up composition |
| CN101716256A (en) * | 2009-12-18 | 2010-06-02 | 威海康博尔生物药业有限公司 | Preparation used for strengthening immunity and inhibiting tumor |
Non-Patent Citations (2)
| Title |
|---|
| 中药喷雾干燥粉末的沸腾制粒工艺;唐雪梅等;《华西药学杂志》;20050626(第03期);第246-248页 * |
| 唐雪梅等.中药喷雾干燥粉末的沸腾制粒工艺.《华西药学杂志》.2005,(第03期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102429929A (en) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113150867B (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| CN101152007B (en) | Health-care products composition and method for preparing the same | |
| CN101357136B (en) | Composition of traditional Chinese medicine effective constituent for preventing and treating diseased associated with cerebral ischemia injury | |
| CN104826087A (en) | Composite moringa polypeptide and preparation method and application thereof | |
| WO2012097579A1 (en) | Pharmaceutical composition for treating melasma and preparation method therefor | |
| CN101724667A (en) | Technology for extracting dendrobium polysaccharide by applying biology engineering enzyme technology and product thereof and application | |
| CN102430110B (en) | CAlprostadil composite medicament of compound fermented cordyceps sinensis powder and alprostadil composite drug | |
| CN105218695B (en) | A kind of lycium ruthenicum polysaccharide extract and preparation method thereof | |
| CN103735662A (en) | Pharmaceutical composition of ginseng and donkey-hide gelatin as well as preparation method and use thereof | |
| CN106491663A (en) | A kind of Phellinus igniarius (L. ex Fr.) Quel. LINGZHI JIAONANG and preparation method thereof | |
| CN104605334A (en) | Cordyceps sinensis oral tablet and preparation method thereof | |
| CN101953857A (en) | Compound fermented cordyceps sinensis bacterium powder (paecilomyces hepiali Cs-4 bacterium powder) composite medicine | |
| CN101810337A (en) | Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali | |
| CN101919892B (en) | Traditional Chinese medicine compound | |
| CN102727863B (en) | Combined drug of compound fermented Cordyceps sinensis powder and ginsenoside Rg1 | |
| CN102429929B (en) | Compound fermented cordyceps fungus powder and taurine combined drug | |
| CN102429931B (en) | Compound fermented cordyceps fungus powder salvianic acid combined drug | |
| CN102600211B (en) | Complex fermented cordycepic fungal powder curcumin combined medicine | |
| CN101991614A (en) | Compound fermented cordyceps sinensis powder (paecilomyces hepiali Cs-4 bacterial powder) combined medicine and preparation thereof | |
| CN102429930B (en) | Compound fermented cordyceps fungus powder and baicalin combined drug, | |
| CN107893035A (en) | A kind of culture medium of Hericium erinaceus, sealwort bioconversion mycelium, the mycelial extract of sealwort bioconversion and application thereof | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN106619783A (en) | Tibetan medicine composition as well as preparation method and application thereof | |
| CN108066350A (en) | The application of forsythin, its derivative, forsythin and phillygenol composition in prevention, treatment senile dementia is prepared | |
| CN101850052A (en) | Immunity-enhancing pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |